Trial reportJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Beneficial effects of Huanglian Jiedu decoction ( ) on metabolic syndrome: a prospective randomized controlled clinical trial.
Trial report in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveTo evaluate the clinical efficacy of Huanglian Jiedu decoction (, HLJDD) in patients with metabolic syndrome (MS) and to elucidate its potential underlying mechanisms.
methodsA total of 132 participants were enrolled and randomly divided into the HLJDD group and the control group. Participants in the HLJDD group received a 3-month HLJDD treatment in addition to lifestyle guidance, while the control group received only lifestyle guidance. Anthropometric indices, blood lipid profiles, liver function indices, glucose homeostasis, insulin sensitivity, inflammatory profiles, and the brown adipokine fibroblast growth factor 21 (FGF-21) were measured both at baseline and at the end of the trial.
resultsThe study demonstrated that administering HLJDD for three months significantly reduces the body weight [8.91% (6.03%-10.22%)
conclusionIt can be concluded that HLJDD contributes to ameliorating metabolic disorders in individuals suffering from metabolic syndrome. The data also imply that the beneficial effects of HLJDD on metabolism might be attributed to its role in enhancing FGF-21 secretion, which is otherwise compromised due to metabolic inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.